Last reviewed · How we verify
NCT02922647: GRECCAR10
Suprapubic Versus Transurethral Catheterization After Rectal Resection With Low Anastomosis for Cancer in Males
NA trial testing suprapubic catheterization in Infection in 240 participants. Completed in 16 April 2021.
18 May 2020
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 240 |
| Start date | 14 October 2016 |
| Primary completion | 18 May 2020 |
| Estimated completion | 16 April 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- suprapubic catheterization
- transurethral catheterization
Conditions studied
Sponsor
University Hospital, Grenoble
Who can join
18 and older, male only, with Infection or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the urinary tract infection rate on the four postoperative day between the 2 groups of patients who have undergone total mesorectal excision for cancer and low anastomosis, with either suprapubic or transurethral catheterization.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Suprapubic versus transurethral catheterization for bladder drainage in male rectal cancer surgery (GRECCAR10), a randomized clinical trial.
Trilling B, Tidadini F, Lakkis Z, Jafari M, et al · · 2024 · cited 2× · PMID 38954131 · DOI 10.1007/s10151-024-02950-2
Verify or expand the search:
- PubMed search for NCT02922647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infection
Currently open trials in the same condition.
- NCT07358117 — Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome · active not recruiting
- NCT07110636 — Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients · NA · recruiting
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT07370948 — Study of the Antibiotic-resistance Profile of Enterobacterales Isolated From Rectal Mucosal Buffer of PrEP Subjects · recruiting
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02922647 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 21 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02922647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing